NewAmsterdam Pharma

NewAmsterdam Pharma is a clinical-stage biotechnology company focused on improving cardiovascular outcomes through next-generation oral LDL-lowering therapies. Its lead drug candidate, obicetrapib, is a potent, selective CETP inhibitor designed to significantly reduce LDL cholesterol when used alone or in combination with statins. The company is advancing a global Phase 3 program evaluating obicetrapib for patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia, with regulatory submissions anticipated upon completion of pivotal trials. Headquartered in the Netherlands, NewAmsterdam is positioning its oral CETP therapy as a scalable, cost-effective alternative to injectable lipid-lowering agents.